Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8+ T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine Authors: Junyan Jin, Xiuwen Wang, Yongzheng Li, Xiaodong Yang, Hu Wang, Xiaoxu Han, Jin Sun, Zhenglai Ma, Junyi Duan, Guanghui Zhang, Tao Huang, Tong Zhang, Hao Wu, Xin Zhang, Bin Su, Yanjie Yin Published: 2023 ABSTRACT AbstractBackground:T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains (TIGIT), an inhibitory receptor expressed on T cells, plays a dysfunctional role in antiviral infection and antitumor activity. However, it is unknown whether TIGIT expression on T cells influences the immunological effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inactivated vaccines.Methods:Forty-five people living with HIV (PLWH) on antiretroviral therapy (ART) for more than two years and 31 healthy controls (HCs), all received a third dose of a SARS-CoV-2 inactivated vaccine, were enrolled in this study. The amounts, activation, proportion of cell subsets, and magnitude of the SARS-CoV-2-specific immune response of TIGIT+CD4+ and TIGIT+CD8+ T cells were investigated before the third dose but 6 months after the second vaccine dose (0W), 4 weeks (4W) and 12 weeks (12W) after the third dose.Results:Compared to that in HCs, the frequency of TIGIT+ CD8+ T cells in the peripheral blood of PLWH increased at 12W after the third dose of the inactivated vaccine, and the immune activation of TIGIT+CD8+ T cells also increased. A decrease in the ratio of both T naïve (TN) and central memory (TCM) cells among TIGIT+CD8+ T cells and an increase in the ratio of the effector memory (TEM) subpopulation were observed at 12W in PLWH. Interestingly, particularly at 12W, a higher proportion of TIGIT+CD8+ T cells expressing CD137 and CD69 simultaneously was observed in HCs than in PLWH based on the activation-induced marker assay. Compared with 0W, SARS-CoV-2-specific TIGIT+CD8+ T-cell responses in PLWH were not enhanced at 12W but were enhanced in HCs. Additionally, at all time points, the SARS-CoV-2-specific responses of TIGIT+CD8+ T cells in PLWH were significantly weaker than those of TIGIT–CD8+ T cells. However, in HCs, the difference in the SARS-CoV-2-specific responses induced between TIGIT+CD8+ T cells and TIGIT–CD8+ T cells was insignificant at 4W and 12W, except at 0W.Conclusions:TIGIT expression on CD8+ T cells may hinder the T-cell immune response to a booster dose of an inactivated SARS-CoV-2 vaccine, suggesting weakened resistance to SARS-CoV-2 infection, especially in PLWH. Furthermore, TIGIT may be used as a potential target to increase the production of SARS-CoV-2-specific CD8+ T cells, thereby enhancing the effectiveness of vaccination.Keywords: HIV, TIGIT, T-lymphocytes, SARS-CoV-2, Booster vaccination, Immunity Introduction In early December 2019, multiple cases of aggravated pneumonia of unknown origin were reported, and were subsequently confirmed to be caused by a novel coronavirus, which spread worldwide and evolved into a pandemic. According to the real-time statistics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) released by the World Health Organization (WHO), as of October 7, 2023, the global cumulative number of confirmed cases of SARS-CoV-2 had surpassed 771 million, with over 6.96 million reported deaths.[1] Vaccination, as a vital means of preventing infection with SARS-CoV-2, has been actively promoted worldwide as an effective measure to control the pandemic.[2,3] It reduces the risk of viral spread and rates of serious illness, thus improving the disease prognosis. At present, SARS-CoV-2 is able to infect vaccinated individuals and reinfections in previously infected individuals are becoming common.[4,5] These infections highlight the need for a broader understanding of the role of vaccination (including booster doses) and natural immunity in the infectiousness of individuals infected with SARS-CoV-2, particularly within populations at a high risk of rapid transmission, such as people living with HIV (PLWH) and immunocompromised populations.[6] After the highly infectious Omicron variant emerged in December 2021, some studies showed a rapid decline in vaccine-boosted neutralizing antibodies against the SARS-CoV-2 Omicron variant.[7,8,9] To date, HIV infection can lead to underlying health problems such as immunodeficiency and chronic inflammation, and PLWH are classified by the WHO as a high-risk group for SARS-CoV-2 infection. Although HIV infection is not a risk factor for SARS-CoV-2 infection, some studies suggest that clinical outcomes are worse in HIV-infected individuals coinfected with SARS-CoV-2 and that the clinical course of PLWH, particularly those with low CD4+ T-cell counts and untreated HIV-infected individuals, may be more severe than in HIV-negative populations.[10,11,12,13,14,15] T cells play a crucial role as orchestrators and effectors in antiviral immunity.[16] Moreover, T cells provide broad-spectrum protection, which is particularly important as novel variants of SARS-CoV-2 emerge.[16,17] Immune checkpoint molecules (ICs) are coinhibitory receptors that downregulate immune responses to prevent hyperimmune activation, reduce collateral damage, and maintain peripheral self-tolerance.[18] ICs are upregulated upon T-cell activation, suppressing the effector response through feedback inhibition. Overexpression of these molecules is associated with T-cell failure and dysfunction in patients with cancer and chronic viral infections, including HIV.[19,20] During HIV infection, high programmed cell death 1 (PD-1) levels are associated with T-cell exhaustion and an incomplete immunological response to ART.[21,22] Several studies have shown that functional blockade of PD-1, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains (TIGIT) facilitates the retention of durable antigen-specific immunity and antiviral effects by CD8+ T cells and that excessive exhaustion of CD8+ T cells in severe SARS-CoV-2 patients may reduce their cellular immune response to SARS-CoV-2.[23,24,25] However, the effects of immune checkpoint upregulation on T-cell effector function, T-cell proliferation, and viral clearance in COVID-19 patients are not well understood,[26,27] which should be a concern for populations with compromised immune systems (such as HIV patients). TIGIT, which belongs to the B7/CD28 superfamily, acts as a coinhibitory molecule not only by directly downregulating the proliferation of human T cells but also by modulating the cytokine secretion of DCs, decreasing IL-12 and enhancing IL-10 production.[28,29] TIGIT has been associated with CD4+ T-cell, CD8+ T-cell, and natural killer (NK)-cell exhaustion in patients with chronic viral infections and malignancies.[30,31,32,33] In addition, TIGIT has been recently associated with CD8+ T-cell dysfunction during HIV infection.[34] It is unclear whether the expression of TIGIT in PLWH affects the immunological effect of SARS-CoV-2 vaccination. To better understand the impact of SARS-CoV-2 vaccination on the immune response of TIGIT-expressing T cells in PLWH, we evaluated the dynamic changes in the amounts, activation, proportion of cell subsets, and magnitude of the SARS-CoV-2-specific immune response associated with TIGIT. This evaluation provides a strategic foundation for modifying the clinical vaccination regimen for HIV-sensitive and specifically immunocompromised populations. Methods Ethics statement This study and the associated experiments received approval from the Beijing Youan Hospital Research Ethics Committee (Nos. 2021-031 and 2021-079), and written informed consent was obtained from each participant under the Declaration of Helsinki. The methods used were in accordance with approved guidelines and regulations. Subjects Forty-five PLWH on suppressive antiretroviral therapy (ART) with undetectable viral load and thirty-one healthy subjects were recruited from Beijing Youan Hospital, China. These subjects were assessed before the third dose but 6 months after the second vaccine dose (0W), 4 weeks (4W) and 12 weeks (12W) after receiving the booster dose. Among PLWH, 27 individuals underwent visits at 0W, 4W and 12W. In addition, 3 individuals underwent visits at 4W and 12W, and other 15 individuals underwent visit at 12W. Among healthy controls (HCs), 31 individuals visited the hospital at 0W, while 23 of these individuals visited the hospital at 4W, and 19 individuals visited the hospital at 12W. Whole blood was collected from the subjects, and then peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque density gradient centrifugation and cryopreserved in liquid nitrogen until needed. CD4+ T-cell count and viral load measurements CD4+ T-cell counts (cells/μL) in the peripheral whole blood of each patient were measured by four-color flow cytometry using BD MultitestTM CD3-FITC/CD8-PE/CD4-APC/CD45-PerCP reagents (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions. Plasma HIV-1 viral load (copies/mL of plasma) was quantified by real-time PCR (Abbott Molecular Inc., Des Plaines, IL, USA). This assay is sensitive for viral RNA detection at 40 copies/mL of plasma. Activation-induced marker (AIM) assay PBMCs were thawed and incubated for 4 hours. Subsequently, 1×106 PBMCs were stimulated with 0.2 μg/mL ancestral strain spike peptide pools and 0.2 μg/mL Omicron spike peptide pools at 37°C with 5% CO2. After 20 hours of stimulation, PBMCs were washed with phosphate buffered saline (PBS) containing 2% fetal bovine serum (FBS) and stained with fluorophore-labeled antibodies targeting surface markers. The following fluorophore-labeled antibodies were used: anti-CD3-PerCP (clone UCHT1; BioLegend, San Diego, CA, USA), anti-CD4-PECy7 (clone RPA-T4; BioLegend), anti-CD8-FITC (clone HIT8α; BD Biosciences), anti-CD45RO-APC750 (clone UCHL1; BioLegend), anti-CCR7-AF700 (clone G043H7; BioLegend), anti-CD137-BV421 (clone 4B4-1; BioLegend), anti-OX40-PE (clone Ber-ACT35; BioLegend), anti-CD38-Brilliant Violet 785 (clone H1T2; BioLegend), anti-HLA-DR-Brilliant Violet 650 (clone L243; BioLegend), and anti-TIGIT-AF594 (clone A15153G; BioLegend). Dead cells were excluded using LIVE/DEAD Fixable Viability Stain 510 (BD Biosciences). The cytometer and tracking calibration particles (BDTM Cytometer Setup & Tracking Beads, BD Biosciences, San Jose, CA, USA) were used to ensure that fluorescence intensity measurements were consistent across all experiments. Flow cytometry Comp-Beads kits (BD Bioscience) were used for compensation. Gating based on forward scatter (FSC) and side scatter (SSC) light was established to exclude cell debris from the analysis; forward height and forward area were used to exclude doublet cells. PBMCs were acquired with a BD LSRFortessaTM flow cytometer (BD Biosciences), and the acquired data were analyzed with FlowJo Software version 10.0 (TreeStar, Ashland, OR, USA). Spike-specific CD4+ T cells were identified using the markers OX40 and CD137 coexpressed on T cells, and spike-specific CD8+ T cells were identified through the coexpression of the markers CD137 and CD69. Statistical analysis Statistical analyses presented in figures were analyzed using GraphPad Prism (version 6.0, Insightful Science, San Diego, CA, USA). For the characteristics of the participants displayed in Table 1, statistical analyses were conducted using IBM SPSS (version 25.0, IBM, Chicago, USA). Categorical variables are expressed as counts and percentages, and continuous variables are expressed as medians and interquartile ranges (IQRs) or mean ± standard deviation according to the data distribution. The significance of differences among multiple variables (parameters at 0W, 4W, and 12W of PLWH and HCs) was analyzed by one-way analysis of variance (ANOVA) or the Kruskal–Wallis test, and then a difference between two variables was determined by Student's t tests or the nonparametric Mann–Whitney U test. Wilcoxon matched pairs test was used for paired observations. Differences were considered statistically significant when the P value was <0.05 in two-tailed tests. Table 1Baseline characteristics of enrolled PLWH and HC who received a third dose of a SARS-CoV-2 inactivated vaccine. Characteristics PLWH (n = 45) HC (n = 31) Statistical values P-values Male43 (95.56%)23 (74.19%)5.580*0.018Age (years)35.0 (31.0–39.5)39.0 (35.0–48.0)–1.620†0.105Most recent CD4 count (cells/µL)571.00 (507.00–863.00)––CD4 count at baseline (cells/µL)587.00 (505.00–807.00)––CD4 count <500 cells/µL11 (24.44%)––CD4 count ≥500 cells/µL34 (75.56%)––Most CD4/CD8 ratio0.76 (0.57–1.04)––Viral load (copies/mL)TND––HBV infection0––HCV infection1 (2.22%)––COVID-19 post-vaccination0––Laboratory examinationWhite blood cell count (×109/L)6.28 (5.15–7.00)6.65 (5.81–7.71)–1.272†0.203Lymphocyte count (×109/L)2.20 ± 0.112.02 ± 0.120.804‡0.105Platelet count (×109/L)247.44 ± 6.85247.00 ± 14.170.029‡0.977ALT (U/L)30.31 (17.00–38.00)24.50 (17.00–37.25)–0.308†0.758AST (U/L)27.82 (21.50–32.00)26.00 (21.00–32.00)–0.523†0.601Data were shown as n (%) or median (interquartile range) or mean ± standard deviation. *χ2 values; †Z values; ‡t values. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; COVID-19: Coronavirus disease 2019; HBV: Hepatitis B virus; HC: Healthy control; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; PLWH: People living with HIV; TIGIT: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains; TND: Test not detected; –: Not applicable. Baseline characteristics of enrolled PLWH and HC who received a third dose of a SARS-CoV-2 inactivated vaccine. Data were shown as n (%) or median (interquartile range) or mean ± standard deviation. *χ2 values; †Z values; ‡t values. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; COVID-19: Coronavirus disease 2019; HBV: Hepatitis B virus; HC: Healthy control; HCV: Hepatitis C virus; HIV: Human immunodeficiency virus; PLWH: People living with HIV; TIGIT: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains; TND: Test not detected; –: Not applicable. Results Demographic and clinical characteristics of the participants In this study, we recruited 45 PLWH and 31 HCs, with the majority of HIV-infected individuals being males. On the same day, just before vaccination, we measured the HIV-1 viral load, CD4+ T-cell count, and CD4+/CD8+ T-cell ratio in HIV-1-infected individuals [Table 1]. As a control group, we enrolled 31 HCs between the interquartile ages of 35 and 48 years. For both groups, PBMCs were collected at all time points: before the third dose but 6 months after the second vaccine dose 0W and at 4W or 12W after receiving the booster dose. An increase in the number of CD8+ T cells expressing TIGIT was observed in PLWH at 12W but not in HCs The flow charts of the flow cytometry gating strategy are shown in Figure 1. As Figure 2A shows, within three months after the third dose of vaccine administration, TIGIT expression on CD4+ T cells in PLWH and HCs remained relatively stable in quantity [Figure 2A]. Moreover, TIGIT-expressing CD8+ T cells in HCs were not upregulated within three months, but an increase in the number of CD8+ T cells expressing TIGIT was observed in PLWH and reached its peak at 12W [Figure 2B]. At 12W, PLWH had a higher proportion of CD8+ T cells expressing TIGIT than HCs [Figure 2B]. Flow cytometry gating strategy for analysis of T-cell phenotypes and immune responses. CD: Cluster of differentiation; FSC-A: Forward scatter-area; FSC-H: Forward scatter-height; SSC-A: Side scatter-area. TIGIT expression on T cells and SARS-CoV-2-specific TIGIT+CD4+ and TIGIT+CD8+ T-cell responses in PLWH and HCs. (A) The frequency of TIGIT+CD4+ T cells; (B) The frequency of TIGIT+CD8+ T cells; (C) The frequency of SARS-CoV-2-specific TIGIT+CD4+ T cells; (D) The frequency of SARS-CoV-2-specific TIGIT+CD8+ T cells. The red dots on the graph represent PLWH; the blue dots represent HCs. HIV (0W): n = 27; (4W): n = 30; (12W): n = 45; HC (0W): n = 31; (4W): n = 23; (12W): n = 19. *P <0.05, †P <0.01, ‡P <0.0001; 0, 4, 12W: At Week 0, Week 4, and Week 12 following inactivated vaccine booster inoculation; CD: Cluster of differentiation; HC: Healthy control; HIV: Human immunodeficiency virus; ns: Not significant; PLWH: People living with HIV; TIGIT: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains. Relatively weak and unenhanced SARS-CoV-2-specific TIGIT+CD8+ T-cell responses in PLWH in comparison to HCs PBMCs were stimulated with a pooled wild-type or Omicron spike protein peptide library to assess whether the magnitude of SARS-CoV-2-specific T-cell responses was influenced by TIGIT expression on CD4+ and CD8+ T cells from PLWH and HCs with a booster inactivated vaccine. This library consisted of 9 to 11 amino-acid length peptides best suited for CD8+ T cells and 15 to 18 amino-acid length peptides best suited for CD4+ T cells. CD4+ and CD8+ T cells were divided into two subpopulations based on whether TIGIT was expressed. Finally, OX40+CD137+CD4+ T cells and CD69+CD137+CD8+ T cells were gated. In this study, stronger SARS-CoV-2-specific TIGIT+CD4+ T-cell responses in HCs than in PLWH were observed at 0W and 4W, but comparable SARS-CoV-2-specific responses were induced between PLWH and HCs at 12W. Interestingly, SARS-CoV-2-specific TIGIT+CD4+ T-cell responses increased substantially in both PLWH and HCs at 12W [Figure 2C]. In contrast, no significant change in SARS-CoV-2-specific TIGIT+CD8+ T-cell responses was observed in PLWH at different time points [Figure 2D]. Notably, SARS-CoV-2-specific TIGIT+CD8+ T-cell responses in HCs were significantly stronger than those in PLWH at 12W [Figure 2D]. For both PLWH and HCs, no significant difference was observed in the SARS-CoV-2-specific TIGIT+CD4+ T-cell or TIGIT+CD8+ T-cell responses, regardless of whether PBMCs were stimulated by the ancestral spike peptide pool or Omicron spike peptide library [Supplementary Figure S1, http://links.lww.com/CM9/B803]. TIGIT+CD8+ T-cell activation was increased in both PLWH and HCs at 12W after inactivated booster vaccination The frequencies of activated TIGIT+CD4+ and activated TIGIT+CD8+ T cells were assessed using CD38 and human leukocyte antigen-DR (HLA-DR) expression, which showed no significant difference in HLA-DR expression on TIGIT+CD4+ and TIGIT+CD8+ T cells [Figure 3A,3B]. Compared to HCs, no difference was observed in the frequency of TIGIT+CD4+ T cells expressing CD38 in PLWH at the three time points [Figure 3C], but the frequencies of TIGIT+CD8+ T cells expressing CD38 were significantly higher in PLWH at 4W and 12W [Figure 3D]. Additionally, the frequency of TIGIT+CD8+ T cells expressing CD38 in PLWH was significantly higher at 12W than at 0W and 4W [Figure 3D]. Changes in the activation of TIGIT+CD4+ T cells and TIGIT+CD8+ T cells in PLWH and HCs after inactivated booster vaccination. (A) The frequency of human leukocyte antigen-DR (HLA-DR)+TIGIT+CD4+ T cells; (B) The frequency of HLA-DR+TIGIT+CD8+ T cells; (C) The frequency of CD38+TIGIT+CD4+ T cells; (D) The frequency of CD38+TIGIT+CD8+ T cells; (E) The frequency of CD38+HLA-DR+TIGIT+CD4+ T cells; (F) The frequency of CD38+HLA-DR+TIGIT+CD8+ T cells. The red dots on the graph represent PLWH; the blue dots represent HCs; HIV (0W): n = 27; (4W): n = 30; (12W): n = 45; HC (0W): n = 31; (4W): n = 23; (12W): n = 19. *P <0.0001, †P <0.01, ‡P <0.05, §P <0.001. 0, 4, 12W: At Week 0, Week 4, and Week 12 following inactivated vaccine booster inoculation; CD: Cluster of differentiation; HC: Healthy control; HLA-DR: Human leukocyte antigen-DR; HIV: Human immunodeficiency virus; ns: Not significant; PLWH: People living with HIV; TIGIT: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains. Generally, gradually upregulated coexpression of CD38 and HLA-DR on TIGIT+CD4+ or TIGIT+CD8+ T cells was observed in both PLWH and HCs [Figure 3E,3F]. Among TIGIT+CD4+ or TIGIT+CD8+ T cells, the coexpression frequency of CD38 and HLA-DR in HCs was higher at 12W than at 0W and 4W. However, in PLWH, significantly higher coexpression of CD38 and HLA-DR was observed at 12W than 0W [Figure 3E,3F]. Nonetheless, at 12W, no difference was observed in the frequency of upregulated CD38 and HLA-DR coexpression on TIGIT+CD4+ or TIGIT+CD8+ T cells between PLWH and HCs [Figure 3E,3F]. Proportion of the TEM subset among TIGIT+CD8+ or TIGIT+CD4+ T cells in PLWH was the highest at 12W Changes in the frequency of T-cell subsets among TIGIT+CD4+ and TIGIT+CD8+ T cells were determined by assessing the cell surface markers CD45RO and CCR7. The differences in the T-cell subsets CD45RO-CCR7+ (naïve T cells, TN), CD45RO+CCR7+ (central memory T cells, TCM), and CD45RO+CCR7- (effector memory T cells, TEM) were evaluated. The proportion of the TCM and TEM subsets among TIGIT+CD4+ T cells in PLWH increased at 12W, but only the proportion of the TCM subset increased in HCs at 12W [Figure 4A]. In PLWH, the ratio of the TN and TCM subsets among TIGIT+CD8+ T cells decreased, while the TEM subset increased at 12W [Figure 4B]. However, the ratio of the TN, TCM and TEM subsets among TIGIT+CD8+ T cells did not change within three months after HCs were inoculated with the third dose of the SARS-CoV-2 inactivated vaccine. Change in the ratio of T-cell subsets among TIGIT+CD4+ T cells and TIGIT+CD8+ T cells in PLWH and HCs after inactivated booster vaccination. (A) The frequency of T-cell subsets among TIGIT+CD4+ T cells in PLWH and HCs; (B) The frequency of cell subsets among TIGIT+CD8+ T cells in PLWH and HCs. *P <0.01, †P <0.001, ‡P <0.05. 0, 4, 12W: At Week 0, Week 4, and Week 12 following inactivated vaccine booster inoculation; CD: Cluster of differentiation; HC: Healthy control; HIV: Human immunodeficiency virus; ns: Not significant; PLWH: People living with HIV; TCM: Central memory T cells (CD45RO+CCR7+); TEM: Effector memory T cells (CD45RO+CCR7-); TN: Naïve T cells (CD45RO-CCR7+); TIGIT: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains. The activation of TIGIT–CD8+ T cells increased in PLWH and HCs at 12W after inactivated booster vaccination The amounts of TIGIT+CD4+ and TIGIT–CD4+ T cells in PLWH or HCs did not change at any time point in this study [Figure 5A]. In PLWH and HCs, the frequency of CD38 and HLA-DR coexpression on both TIGIT+CD4+ and TIGIT–CD4+ T cells increased, reaching a peak at 12W [Figure 5B]. Interestingly, the upregulated activation of TIGIT+CD4+ T cells in PLWH started from 4W, while TIGIT+CD4+ T-cell activation in HC was significantly enhanced at 12W [Figure 5B]. Changes in the amounts and activation of T cells with positive TIGIT expression or not in PLWH and HCs. (A) The frequency of TIGIT+ and TIGIT–CD4+ T cells in PLWH and HCs after inactivated booster vaccination; (B) The frequency of CD38 and HLA-DR coexpression in TIGIT+CD4+ and TIGIT–CD4+ T cells after inactivated vaccine booster inoculation; (C) The frequency of TIGIT+ and TIGIT–CD8+ T cells in PLWH and HCs after inactivated vaccine booster inoculation; (D) The frequency of CD38andHLA-DR coexpression on TIGIT+CD8+ and TIGIT–CD8+ T cells after inactivated vaccine booster inoculation. Blue triangles represent TIGIT–CD4+T cells or TIGIT–CD8+T cells; red triangles represent TIGIT+CD4+T cells or TIGIT+CD8+T cells. HIV (0W): n = 27; (4W): n = 30; (12W): n = 45; HC (0W): n = 31; (4W): n = 23; (12W): n = 19. *P <0.05, †P <0.01, ‡P <0.001, §P <0.0001. 0, 4, 12W: At Week 0, Week 4, and Week 12 following inactivated vaccine booster vaccination; CD: Cluster of differentiation; HC: Healthy control; HLA-DR: Human leukocyte antigen-DR; HIV: Human immunodeficiency virus; ns: Not significant; PLWH: People living with HIV; TIGIT: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains. At each time point in this study, there was almost no change in the proportions of either TIGIT+CD8+ or TIGIT–CD8+ T cells in HCs. In contrast to HCs, the proportions of TIGIT+CD8+ T cells increased but those of TIGIT–CD8+ T cells decreased in PLWH and peaked at 12W [Figure 5C]. In PLWH, the activation of CD38 and HLA-DR coexpressed on both TIGIT+CD8+ and TIGIT–CD8+ T cells increased, reaching a peak at 12W [Figure 5D]. In HCs, the levels of activated TIGIT+CD8+ T cellssignificantly decreased at 4W and then significantly increased at 12W, and the activation of TIGIT–CD8+ T cells in HCs also significantly increased at 12W [Figure 5D]. Weaker SARS-CoV-2-specific TIGIT+CD8+ T-cell responses than TIGIT–CD8+ T-cell responses were observed in PLWH at different time points There was no significant difference in the levels of SARS-CoV-2-specific T-cell responses induced between TIGIT–CD4+ and TIGIT+CD4+ T cells at 0W and 4W in both PLWH and HCs [Figure 6A]. However, at 12W, more TIGIT+CD4+ T cells in PLWH were induced to coexpress the markers CD137 and OX40 than TIGIT–CD4+ T cells, while there was no difference in HCs [Figure 6A]. Moreover, outcomes in this study displayed an augmentation of SARS-CoV-2-specific T-cell responses elicited on TIGIT–CD8+ T cells compared to TIGIT+CD8+ T cells in PLWH at all time points after booster vaccination [Figure 6B]. In contrast to PLWH, a significant difference in SARS-CoV-2-specific T-cell responses induced between TIGIT–CD8+ and TIGIT+CD8+ T cells in HCs was not observed at 4W and 12W, except at 0W. [Figure 6B]. Changes in the magnitude of SARS-CoV-2-specific T-cell responses in T cells with or without TIGIT expression in PLWH and HCs. (A) The magnitude of SARS-CoV-2-specific TIGIT+CD4+ T-cell responses compared to that on TIGIT–CD4+ T cells in PLWH and HCs; (B) The magnitude of SARS-CoV-2-specific TIGIT+CD8+ T-cell responses compared to that on TIGIT–CD8+ T cells in PLWH and HCs. HIV (0W): n = 27; (4W): n = 30; (12W): n = 45; HC (0W): n = 31; (4W): n = 23; (12W): n = 19. Blue triangles represent TIGIT–CD4+ T cells or TIGIT–CD8+ T cells; red triangles represent TIGIT+CD4+ T cells or TIGIT+CD8+ T cells. Wilcoxon matched pairs test was used for paired observations. *P <0.01, †P <0.05, ‡P <0.0001. 0, 4, 12W: At Week 0, Week 4, and Week 12 following inactivated vaccine booster inoculation; CD: Cluster of differentiation; HC: healthy control; HIV: Human immunodeficiency virus; ns: Not significant; PLWH: People living with HIV; TIGIT: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains. Discussion In HIV-1 individuals who are not receiving ART, continued exposure to antigens leads to progressive exhaustion of HIV-specific CD4+ and CD8+ T cells.[35,36] Multiple inhibitory molecules are upregulated under chronic antigen-stimulating conditions and then impair HIV-specific CD8+ T cells in their antiviral function.[20,37,38,39] Overexpression of CTLA4, PD-1 and TIGIT on CD8+ T cells reduces effector CD8+ T cells and prevents their proliferation.[40] This study was mainly focused on the changes in the amounts, activation, cell subset composition, and SARS-CoV-2-specific T-cell responses in TIGIT-expressing T cells in PLWH and HCs after receiving a third dose of a SARS-CoV-2 inactivated vaccine. The number of TIGIT+CD8+ T cells in PLWH significantly increased at 12W but not at 0W or 4W, while this increase was not observed in HCs, suggesting that disease status might promote the expression of TIGIT on CD8+ T cells. TIGIT expression on T cells has been reported to be associated with HIV pathogenesis mediated by host immune activation during HIV infection.[41] Significantly increased activation of TIGIT+CD8+ T cells in PLWH was observed at 12W in this study. Furthermore, the activation of TIGIT+CD8+ T cells in PLWH was stronger than that in HCs at 4W and 12W, but comparable activation was observed at 0W between PLWH and HCs [Figure 3D]. Thus, enhanced immune activation might be a factor contributing to the increase in the number of TIGIT+CD8+ T cells in PLWH at 12W. As for CD4+ T cells, the number of TIGIT+CD4+ T cells did not increase in either PLWH or HCs within three months, although the activation of TIGIT+CD4+ T cells was significantly heightened at 12W after booster vaccine inoculation. The underlying factors regarding this distinct difference need to be further explored. It has been reported that inoculation with the ChAdOx1nCoV-19 (AZD1222 AstraZeneca, London, UK) vaccine itself may lead to a small but significant increase in CD4 and CD8 T-cell activation.[42] In this study, more TIGIT+CD8+ and TIGIT+CD4+ T cells in PLWH and HCs were activated at 12W; additionally, more activated TIGIT+CD8+ T cells but not more activated TIGIT+CD4+ T cells were observed in PLWH than in HCs [Figure 3]. Moreover, the activation of TIGIT+CD8+ T cells in HCs was weaker than that in PLWH at 4W and 12W. These results showed that vaccination may promote T-cell activation in PLWH and HCs but that it might aggravate the activation of TIGIT+CD8+ T cells in people living with HIV. Chronic immune activation in HIV-1 individuals may affect the vaccine response.[42] Although activated TIGIT+CD8+ T cells increased in quantity, SARS-CoV-2-specific TIGIT+CD8+ T-cell responses in PLWH were not strengthened [Figure 2D]. In contrast, SARS-CoV-2-specific TIGIT+CD8+ T-cell responses in HCs gradually increased and peaked at 12W, though the activated TIGIT+CD8+ T cells in HCs decreased at 4W and then increased at 12W. In addition, SARS-CoV-2-specific TIGIT+CD8+ T-cell responses in HCs were stronger than those in PLWH at 4W and especially at 12W. These outcomes showed that the recall response of TIGIT+CD8+ T cells in PLWH to vaccine antigens was relatively weak, which suggested that heightened immune activation due to HIV-1 infection had an negative impact on recall. TIGIT can be upregulated upon T-cell activation to suppress the CD8 T-cell effector response to clear infected targets through feedback inhibition in viral infection.[43] Of note, a significantly weaker SARS-CoV-2-specific TIGIT+CD8+ T-cell response than TIGIT–CD8+ T-cell response was observed in PLWH at each time point, but a similar magnitude recall response was observed for TIGIT+CD8+ and TIGIT–CD8+ T cells in HCs at 4W and 12W [Figure 6B]. The above results indicate that the recall response of TIGIT+CD8+ T cells to SARS-CoV-2 vaccine booster inoculation in HIV-1 individuals was suppressed but that of TIGIT–CD8+ T cells was not. Thus, the activation of TIGIT–CD8+ T cells in response to vaccine antigens is crucial for combating SARS-CoV-2 infection in HIV-1 individuals. Additionally, this study showed that PLWH inoculated with inactivated booster vaccines exhibited an increase in SARS-CoV-2-specific TIGIT–CD8+ T cells, suggesting that vaccination with inactivated booster vaccines is important for controlling SARS-CoV-2 infection, which is similar to our previous findings in HCs.[44] The number of TIGIT+CD4+ T cells in PLWH and HCs remained unchanged, but activation was significantly increased at 12W after the third dose of vaccine. Notably, SARS-CoV-2-specific TIGIT+CD4+ T cells substantially increased at 12W in PLWH and HCs. Nonetheless, there was no difference in the number, activation or SARS-CoV-2-specific T-cell responses in TIGIT+CD4+ T cells between PLWH and HCs at 12W. In addition, comparable SARS-CoV-2-specific T-cell responses were induced in TIGIT+CD4+ T cells and TIGIT–CD4+ T cells from PLWH or HCs at each time point, except for stronger SARS-CoV-2-specific TIGIT+CD4+ T-cell response observed in PLWH at 12W compared to TIGIT–CD4+ T cells. The above results indicate that HIV-1 infection and TIGIT expression have a little effect on the immune response of TIGIT+ CD4+ T cells in PLWH and HCs after vaccination. Compared to TIGIT–CD4+ T cells, comparable SARS-CoV-2-specific CD4 T-cell responses were elicited on TIGIT+CD4+ T cells in PLWH at 0W and 4W, but enhanced SARS-CoV-2-specific TIGIT+CD4+ T-cell response induced in PLWH at 12W, which was different from the result between TIGIT–CD8+ T cells and TIGIT+CD8+ T cells. We speculate that the possible explanation for this discrepancy is that the incubation time of OX40 in our study was insufficient, resulting in insufficient expression of OX40.[45] Further studies are needed to verify the expression of OX40 in CD4+ T cells in the future. After SARS-CoV-2 inactivated vaccine booster inoculation, the ratio of cell subsets among TIGIT+CD8+ T cells in HCs remained almost unchanged. However, this homeostasis in TIGIT+CD8+ T cells in PLWH was disrupted, with a decrease in the TCM subset but an increase in the TEM subset, especially at 12W. This difference in the distribution of memory CD8 T-cell subpopulations among TIGIT+CD8+ T cells may suggest a significant difference in the types of memory cells induced by SARS-CoV-2 vaccines between HIV and healthy individuals. Higher frequencies of naïve T cells have been linked with better COVID-19 outcomes not only in PLWH but also in the general population, including children, and naïve T cells are a key component in COVID-19 severity.[46,47] In a study on cellular immune responses induced by HIV vaccination with 3 doses of mRNA vaccine, a decrease in naïve CD8+ T cells was observed in PLWH compared to controls.[48] It was also observed in our study that the ratio of the TN subset among TIGIT+CD8+ T cells decreased in PLWH. There are several limitations to this study. First, this study mainly examined subjects receiving ART whose CD4+ T-cell counts were above 200 cells/µl and viral load was below the detection limit. Therefore, the immune responses observed may not be entirely representative of those HIV-1 individuals with poor immune statuses, such as low CD4+ T-cell counts, high viral load or other demographically distinct cohorts. Second, the study did not further investigate whether sex affects the immune response to booster vaccination, which needs to be investigated in the future with a larger sample size. Taken together, this study mainly displayed differences in the frequency, activation, cell homeostasis, and SARS-CoV-2-specific T-cell responses of T cells expressing TIGIT between PLWH and HCs after inactivated vaccine booster inoculation. Compared to HCs, HIV-1 individuals have more TIGIT-expressing CD8+ T cells and fewer SARS-CoV-2-specific T cells among TIGIT+CD8+ T cells. TIGIT expression hinders the specific T-cell immune response to vaccine antigens and may weaken resistance to SARS-CoV-2 infection. In addition to implications for clinical decision-making and public health policy for the prevention of SARS-CoV-2 infection in PLWH, this study provides insights into the activation and function of T cells expressing TIGIT. Conflicts of interest None. Funding This project is financially supported by Beijing Natural Science Foundation (No. L222068 to Bin Su), the National Natural Science Foundation of China (NSFC, No. 82272319 to Hu Wu, and No. 81974303 to Bin Su), the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission (No. 2022-2-018 to Bin Su, and No. 2022-1-007 to Tong Zhang), the Climbing the peak (Dengfeng) Talent Training Program of Beijing Hospitals Authority (No. DFL20191701 to Tong Zhang), the Beijing Health Technologies Promotion Program (No. BHTPP202002 to Tong Zhang), and Beijing Key Laboratory for HIV/AIDS Research (No. BZ0089). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Supplementary Material SUPPLEMENTARY MATERIAL Footnotes Junyan Jin, and Xiuwen Wang contributed equally to this study. How to cite this article: Jin JY, Wang XW, Li YZ, Yang XD, Wang H, Han XX, Sun J, Ma ZL, Duan JY, Zhang GH, Tao H, Zhang T, Wu H, Zhang X, Su B. Weak SARS-CoV-2-specific responses of TIGITexpressing CD8+ T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine. Chin Med J 2023;136:2938–2947 doi: 10.1097/CM9.0000000000002926 References Associated Data Supplementary Materials SUPPLEMENTARY MATERIAL